Description

Glaukos Corporation: Can The iDose Market Expansion Fetch Significant Growth With iDose Platform? 

Glaukos Corporation’s financial results for the fourth quarter and full year 2024 reflect strong performance across multiple segments and considerable strategic initiatives, setting up the company for continued development in the upcoming year. The company reported record fourth quarter consolidated net sales of $105.5 million, marking a 28% increase compared to the same period in the previous year. For the full year, Glaukos achieved net sales of $383.5 million, representing a 22% increase over 2023. Furthermore, the company introduced guidance for 2025, expecting net sales between $475 million and $485 million.

Our Report Structure:

⦁ Company Overview
⦁ Investment Thesis
⦁ Key Drivers
⦁ Historical Quarterly Statement Analysis – Income Statement & Cash Flows
⦁ Historical Quarterly Balance Sheet Analysis
⦁ Historical Annual Financial Statement Analysis
⦁ Analysis Of Key Financial Ratios
⦁ Financial Forecasts For 3 Years
⦁ Forecasting The Capital Structure & Net Debt
⦁ Discounted Cash Flow Valuation
⦁ Trading Multiples
⦁ Key Risks
⦁ Disclosures

Want unlimited access to our reports? Purchase our $99 annual subscription!